125 related articles for article (PubMed ID: 38575047)
1. Combining raloxifene and mechanical loading improves bone composition and mechanical properties in a murine model of chronic kidney disease (CKD).
Surowiec RK; Reul ON; Chowdhury NN; Rai RK; Segvich D; Tomaschke AA; Damrath J; Jacobson AM; Allen MR; Wallace JM
Bone; 2024 Jun; 183():117089. PubMed ID: 38575047
[TBL] [Abstract][Full Text] [Related]
2. Ex vivo exposure to calcitonin or raloxifene improves mechanical properties of diseased bone through non-cell mediated mechanisms.
Surowiec RK; Saldivar R; Rai RK; Metzger CE; Jacobson AM; Allen MR; Wallace JM
Bone; 2023 Aug; 173():116805. PubMed ID: 37196853
[TBL] [Abstract][Full Text] [Related]
3. Effects of novel raloxifene analogs alone or in combination with mechanical loading in the Col1a2
Kohler R; Creecy A; Williams DR; Allen MR; Wallace JM
Bone; 2024 Feb; 179():116970. PubMed ID: 37977416
[TBL] [Abstract][Full Text] [Related]
4. Raloxifene improves skeletal properties in an animal model of cystic chronic kidney disease.
Newman CL; Creecy A; Granke M; Nyman JS; Tian N; Hammond MA; Wallace JM; Brown DM; Chen N; Moe SM; Allen MR
Kidney Int; 2016 Jan; 89(1):95-104. PubMed ID: 26489025
[TBL] [Abstract][Full Text] [Related]
5. Cortical porosity development and progression is mitigated after etelcalcetide treatment in an animal model of chronic kidney disease.
Swallow EA; Metzger CE; Newman CL; Chen NX; Moe SM; Allen MR
Bone; 2022 Apr; 157():116340. PubMed ID: 35085840
[TBL] [Abstract][Full Text] [Related]
6. Raloxifene reduces skeletal fractures in an animal model of osteogenesis imperfecta.
Berman AG; Wallace JM; Bart ZR; Allen MR
Matrix Biol; 2016; 52-54():19-28. PubMed ID: 26707242
[TBL] [Abstract][Full Text] [Related]
7. Limited impacts of thermoneutral housing on bone morphology and mechanical properties in growing female mice exposed to external loading and raloxifene treatment.
Tastad CA; Kohler R; Wallace JM
Bone; 2021 May; 146():115889. PubMed ID: 33618075
[TBL] [Abstract][Full Text] [Related]
8. Effects of Raloxifene and tibial loading on bone mass and mechanics in male and female mice.
Berman AG; Damrath JG; Hatch J; Pulliam AN; Powell KM; Hinton M; Wallace JM
Connect Tissue Res; 2022 Jan; 63(1):3-15. PubMed ID: 33427519
[No Abstract] [Full Text] [Related]
9. Zoledronate and Raloxifene combination therapy enhances material and mechanical properties of diseased mouse bone.
Powell KM; Skaggs C; Pulliam A; Berman A; Allen MR; Wallace JM
Bone; 2019 Oct; 127():199-206. PubMed ID: 31233931
[TBL] [Abstract][Full Text] [Related]
10. The combination of aging and chronic kidney disease leads to an exacerbated cortical porosity phenotype.
Tippen SP; Metzger CE; Swallow EA; Sacks SA; Wallace JM; Allen MR
Bone; 2022 Jan; 154():116228. PubMed ID: 34624561
[TBL] [Abstract][Full Text] [Related]
11. Adenine-induced chronic kidney disease induces a similar skeletal phenotype in male and female C57BL/6 mice with more severe deficits in cortical bone properties of male mice.
Metzger CE; Swallow EA; Stacy AJ; Allen MR
PLoS One; 2021; 16(4):e0250438. PubMed ID: 33891630
[TBL] [Abstract][Full Text] [Related]
12. Raloxifene Improves Bone Mechanical Properties in Mice Previously Treated with Zoledronate.
Meixner CN; Aref MW; Gupta A; McNerny EMB; Brown D; Wallace JM; Allen MR
Calcif Tissue Int; 2017 Jul; 101(1):75-81. PubMed ID: 28246928
[TBL] [Abstract][Full Text] [Related]
13. Changes in skeletal collagen cross-links and matrix hydration in high- and low-turnover chronic kidney disease.
Allen MR; Newman CL; Chen N; Granke M; Nyman JS; Moe SM
Osteoporos Int; 2015 Mar; 26(3):977-85. PubMed ID: 25466530
[TBL] [Abstract][Full Text] [Related]
14. Reversing cortical porosity: Cortical pore infilling in preclinical models of chronic kidney disease.
Metzger CE; Swallow EA; Stacy AJ; Tippen SP; Hammond MA; Chen NX; Moe SM; Allen MR
Bone; 2021 Feb; 143():115632. PubMed ID: 32927105
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of RANKL improves the skeletal phenotype of adenine-induced chronic kidney disease in mice.
Metzger CE; Kittaka M; LaPlant AN; Ueki Y; Allen MR
JBMR Plus; 2024 Feb; 8(2):ziae004. PubMed ID: 38505524
[TBL] [Abstract][Full Text] [Related]
16. A novel murine model of combined insulin-dependent diabetes and chronic kidney disease has greater skeletal detriments than either disease individually.
Damrath JG; Metzger CE; Allen MR; Wallace JM
Bone; 2022 Dec; 165():116559. PubMed ID: 36116758
[TBL] [Abstract][Full Text] [Related]
17. Strain-specific alterations in the skeletal response to adenine-induced chronic kidney disease are associated with differences in parathyroid hormone levels.
Metzger CE; Swallow EA; Stacy AJ; Allen MR
Bone; 2021 Jul; 148():115963. PubMed ID: 33878503
[TBL] [Abstract][Full Text] [Related]
18. Parathyroid suppression therapy normalizes chronic kidney disease-induced elevations in cortical bone vascular perfusion: a pilot study.
Aref MW; Swallow EA; Metzger CE; Chen N; Moe SM; Allen MR
Osteoporos Int; 2019 Aug; 30(8):1693-1698. PubMed ID: 31069439
[TBL] [Abstract][Full Text] [Related]
19. Compromised vertebral structural and mechanical properties associated with progressive kidney disease and the effects of traditional pharmacological interventions.
Newman CL; Chen NX; Smith E; Smith M; Brown D; Moe SM; Allen MR
Bone; 2015 Aug; 77():50-6. PubMed ID: 25892482
[TBL] [Abstract][Full Text] [Related]
20. Cortical porosity is elevated after a single dose of zoledronate in two rodent models of chronic kidney disease.
Swallow EA; Metzger CE; Chen NX; Wallace JM; Tippen SP; Kohler R; Moe SM; Allen MR
Bone Rep; 2022 Jun; 16():101174. PubMed ID: 35252482
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
